I’m a (Biosimilars) Believer!
It’s been a long winding journey, but biosimilars are finally starting to shake up the biopharma market. Their true potential remains untapped, however – hindered by market access and myths around safety. Here, four biosimilar gurus discuss successes and tackle the issues head on. “Biosimilars have had many challenges coming to the US market, including struggles with channel, payer and pricing strategies. Though we’ve worked extensively with our manufacturer partners on all three, right now, we are finding that there is a need to focus on responsible pricing. Biosimilar manufacturers need to be careful when devising their pricing strategy, as collectively it is what upholds the market,” said Rick Lozano, Vice President, Biosimilars & Integrated Business Development at AmerisourceBergen.
For the full article, visit The Medicine Maker.